Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Majore depression

Ketamine-containing nasal spray approved in Switzerland

    • General Internal Medicine
    • Market & Medicine
    • Psychiatry and psychotherapy
    • RX
    • Studies
  • 2 minute read

Following the EU, Switzerland has also recently approved a nasal spray based on the active ingredient ketamine, which is known as a party drug. The preparation can be used as an add-on in case of therapy resistance.

The drug Spravato® (esketamine) is approved in combination with an SSRI (selective serotonin reuptake inhibitor) or SNRI (selective norepinephrine reuptake inhibitor) for adults with treatment-resistant major depression [1]. Treatment resistance is defined as a lack of response to at least two different antidepressants [2]. The approval is based on five phase III studies: three short-term studies, one long-term safety study, and one randomized relapse prevention study [2].

Very rapid onset of action

The great advantage of esketamine is that it acts comparatively quickly. In pivotal trials, more than 1600 patients over the age of 18 years with treatment-resistant depression received esketamine nasal spray combined with a newly administered oral antidepressant [2]. In the short-term studies, a clinically significant response was measurable in the verum group up to 28 days after baseline.  Response was defined as a reduction in total Montgomery-Asberg Depression Rating Scale (MADRS) score of at least 50% from baseline in the induction phase. In the multicenter, randomized, double-blind, active-controlled, long-term relapse prevention trial, esketamine nasal spray combined with an antidepressant reduced the risk of relapse by 70% in patients with stable response compared with the placebo group. In patients in stable remission, the risk of recurrence decreased by 51%. The long-term safety study found that even with up to 52 weeks of therapy, esketamine nasal was generally well tolerated.

The antidepressant effect probably occurs via antagonism at the NMDA receptor. This provides a transient increase in glutamate release that leads to increased stimulation of the AMPA receptor and subsequently increased neurotrophin-induced signal transduction, which may contribute to restored synaptic function in brain regions responsible for mood and emotion regulation [3].

Blood pressure control recommended

The nasal spray is a single-use applicator containing a total of 28 mg of esketamine divided into two sprays (one spray per nostril). The nasal spray is intended for use by the patient himself/herself under the supervision of healthcare professionals, according to the respective dosage recommendations. Before using the nasal spray, the patient’s blood pressure must be measured. If baseline blood pressure is elevated, the risks associated with short-term elevated blood pressure levels must be weighed against the benefits of treatment. The spray must not be used if increased blood pressure or increased intracranial pressure poses a serious risk. Blood pressure should be checked approximately 40 minutes after application of Spravato® and again thereafter at clinical discretion [3].

Source: Janssen-Cilag International

 

Literature:

  1. Mahase E: Esketamine is approved in Europe for treating resistant major depressive disorder. BMJ 2019; 367: l7069.
  2. European Medicines Agency. Esketamine nasal spray Summary of Product Characteristics, www.ema.europa.eu/en/medicines
  3. Siebenand S: Esketamine nasal spray approved for depression. Pharmaceutical Journal, Dec. 23, 2019, www.pharmazeutische-zeitung.de
  4. Swissmedics: Spravato®, nasal spray (esketaminum), www.swissmedic.ch

 

HAUSARZT PRAXIS 2020; 15(4): 27

Autoren
  • Mirjam Peter, M.Sc.
Publikation
  • HAUSARZT PRAXIS
Related Topics
  • AMPA receptor blood pressure control
  • Esketamine
  • Ketamine-containing
  • MADRS
  • Majore depression
  • Montgomery-Asberg Depression Rating Scale
  • Nasal spray
  • NMDA receptor
  • SNRI
  • Spravato®
  • SSRI
  • treatment-resistant
Previous Article
  • Psychooncology

Communication is the key to adherence

  • Education
  • General Internal Medicine
  • Prevention and health care
  • RX
View Post
Next Article
  • Digitization

The trend is toward telemedicine – not only because of COVID-19

  • General Internal Medicine
  • Infectiology
  • News
  • Prevention and health care
  • RX
View Post
You May Also Like
View Post
  • 7 min
  • Moderate to severe chronic hand eczema

Delgocitinib cream – first topical pan-JAK inhibitor approved in Switzerland

    • Allergology and clinical immunology
    • Dermatology and venereology
    • Education
    • Infectiology
    • Market & Medicine
    • Pharmacology and toxicology
    • RX
View Post
  • 9 min
  • Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CA)

Diagnosis at an early stage, prognostic classifications and outlook

    • Cardiology
    • Education
    • RX
    • Studies
View Post
  • 4 min
  • Case report: Drug-induced hepatitis

Rare side effect of tirzepatide therapy

    • Cases
    • Education
    • Endocrinology and Diabetology
    • Gastroenterology and Hepatology
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 4 min
  • Plea for sex-specific neurology

Migraine in men: underdiagnosed, underestimated, under-researched

    • Education
    • Neurology
    • RX
    • Studies
View Post
  • 4 min
  • Prurigo nodularis

Retrospective analyses of large data sets from everyday practice

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • RX
View Post
  • 3 min
  • Public Health

Outpatient care in Switzerland: situation report

    • General Internal Medicine
    • Practice Management
    • Prevention and health care
    • RX
View Post
  • 5 min
  • Practice Management

Improved quality of care aims for satisfied patients

    • CME continuing education
    • General Internal Medicine
    • Practice Management
    • Prevention and health care
    • RX
    • Studies
View Post
  • 30 min
  • Chemsex - MSM, sex, chrystal meth & co.

Medical and psychosocial perspectives

    • CME continuing education
    • General Internal Medicine
    • Infectiology
    • Pharmacology and toxicology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • RX
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.